This contributor column discusses a recent study that shows the 340B Program’s explosive growth is overwhelmingly due to utilization increases, not price.
William A. Sarraille, JD
Advertisement
William A. Sarraille JD, is Professor of Practice, University of Maryland Francis King Carey School of Law.
ORCID ID: 0009-0008-0593-0473
Articles by William A. Sarraille, JD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Nerandomilast for Idiopathic Pulmonary Fibrosis
2
FDA Approves Cemiplimab as First, Only Adjuvant Immunotherapy for High-Risk CSCC
3
Pulling Back Funding for Research Could Leave HIV Treatment in Worse State: Patrick Sullivan, DVM, PhD
4
Flow Cytometry Tool Could Improve Treatment Monitoring in MS
5
